(Q44078515)

29 November 2017

title

Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder (English)

1 reference

29 November 2017

0 references

Anne Klibanski

6

1 reference

29 November 2017

Carla M Canuso

1

1 reference

29 November 2017

Jill M Goldstein

2

1 reference

29 November 2017

Joanne Wojcik

3

1 reference

29 November 2017

Ree Dawson

4

1 reference

29 November 2017

Danielle Brandman

5

1 reference

29 November 2017

Joseph J Schildkraut

7

1 reference

29 November 2017

Alan I Green

8

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

111

1 reference

29 November 2017

issue

1

1 reference

29 November 2017

page(s)

11-20

1 reference

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Attenuation of antipsychotic-induced hyperprolactinemia with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Olanzapine use in women with antipsychotic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

The effect of chronic neuroleptic treatment on gonadotrophin release.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Prevalence and predictors of depressive symptoms in older premenopausal women: the Harvard Study of Moods and Cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Estradiol levels in psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Clozapine: plasma levels and prolactin response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Varying body mass index cutoff points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

A clinical trial of the effects of estrogen in acutely psychotic women

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

A study of serum prolactin levels in schizophrenia: comparison of males and females

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Hypothalamic amenorrhea: clinical perspectives, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Serum gonadal steroid hormones in young schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Effects of chlorpromazine on pituitary function.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Can estradiol modulate schizophrenic symptomatology?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

Clinical trials with melleril (TP21) in the treatment of schizophrenia. A two year study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

The role of estrogens in schizophrenia gender differences

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-1781%2802%2900123-3

1 reference

7 January 2021

10.1016/S0165-1781(02)00123-3

Identifiers

DOI

1 reference

29 November 2017

1 reference